Sanofi Total Long-Term Assets 2010-2024 | SNY

Sanofi total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Sanofi total long-term assets for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi total long-term assets for 2023 were $103.678B, a 6.16% increase from 2022.
  • Sanofi total long-term assets for 2022 were $97.665B, a 7.95% decline from 2021.
  • Sanofi total long-term assets for 2021 were $106.098B, a 14.91% increase from 2020.
Sanofi Annual Total Long-Term Assets
(Millions of US $)
2023 $103,678
2022 $97,665
2021 $106,098
2020 $92,328
2019 $94,220
2018 $102,545
2017 $83,048
2016 $86,298
2015 $85,937
2014 $98,322
2013 $95,841
2012 $99,810
2011 $110,459
2010 $77,264
2009 $78,342
Sanofi Quarterly Total Long-Term Assets
(Millions of US $)
2024-09-30
2024-06-30 $107,341
2024-03-31
2023-12-31 $103,678
2023-09-30
2023-06-30 $103,999
2023-03-31
2022-12-31 $97,665
2022-09-30
2022-06-30 $99,467
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $83,048
2017-09-30
2017-06-30 $82,294
2017-03-31
2016-12-31 $86,298
2016-09-30
2016-06-30 $86,728
2016-03-31
2015-09-30
2015-06-30 $83,976
2014-06-30 $96,508
2013-06-30 $99,483
2012-06-30 $103,187
2012-03-31
2011-12-31 $95,486
2011-09-30
2011-06-30 $95,383
2011-03-31
2010-12-31 $66,435
2010-09-30
2010-06-30 $67,660
2010-03-31
2009-12-31 $67,422
2009-09-30
2009-06-30 $69,023
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $121.816B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Innoviva (INVA) United States $1.195B 9.94